NOXXON Pharma was formed to commercialize the research-elucidated methodology of generating Spiegelmers®. The company’s business strategy reflects the aim of many speciality pharmas to develop from a platform technology company into a fully integrated pharmaceutical business. NOXXON’s technology platform is an innovative, extensively patented methodology to develop mirror-image nucleic acids, Spiegelmers next-generation aptamers as biopharmaceutical therapeutics.